Tau Powers Memory, a Kidney Drug Makes History, and Legionnaires' Spreads in Manhattan

Alzheimer's research, a landmark kidney drug, brain changes across two pregnancies, and two active outbreaks — a full week's worth of medicine in five stories.

Alzheimer's Tau Has a Hidden Healthy Role — New Research Reframes How Memory Forms

A study published on 10 July 2026 has revealed that tau — the protein most associated with Alzheimer's disease pathology — plays an indispensable role in normal, healthy memory formation. Researchers found that tau is not required for learning something new, nor for recalling it minutes later; instead, it becomes critical for converting short-term experiences into durable, long-lasting memories.

The mechanism involves a process called phosphorylation: during learning, tau undergoes controlled, low-level chemical modification that helps coordinate the activity of so-called engram cells — the sparse constellations of neurons in which specific memories are encoded. In Alzheimer's disease, this same phosphorylation process goes awry, with tau becoming abnormally and excessively modified, aggregating into neurofibrillary tangles that disrupt neuronal signalling. The new research was published ahead of the Alzheimer's Association International Conference (AAIC) taking place this week (12–15 July) in London, where major new data from tau-directed clinical trials are expected.

The findings add both scientific depth and caution to therapeutic strategies targeting tau. Eliminating tau entirely may impair healthy memory consolidation as well as pathological accumulation — meaning dose and selectivity will matter greatly for drugs now in development. Tau pathology correlates more closely with clinical decline in Alzheimer's than amyloid burden alone, which is why much of the field's next generation of interventions is now focusing here. Antisense oligonucleotide therapies such as diranersen are among the approaches entering later-stage trials.

Every Pregnancy Rewires the Brain in Its Own Way — A Longitudinal Study of 110 Women

A study from Amsterdam UMC, published 11 July 2026 in Nature Communications, followed 110 women over time — some pregnant with their first child, some with their second, others remaining childless — and found that a second pregnancy produces a distinct pattern of brain changes that does not simply repeat the first.

During a first pregnancy, the largest brain changes occur in the default mode network — the neural system most strongly linked to introspection, self-identity, and the initiation of maternal bonding and caregiving behaviour. In a second pregnancy, those default-mode shifts are less pronounced (the first pregnancy having already reshaped maternal neural circuitry), but significant remodelling occurs instead in brain regions governing attention and the processing of visual and auditory stimuli. The researchers interpret this as the brain adapting to what is situationally new: a first-time mother is restructuring her identity and learning caregiving from scratch; a second-time mother is equipping herself to attend to multiple children simultaneously.

The authors note that the findings have clinical relevance for understanding postpartum depression, which may manifest differently across pregnancies, and for tailoring mental health support accordingly. This is a peer-reviewed neuroimaging study with a longitudinal design and a well-characterised cohort — a more methodologically robust basis for these conclusions than most observational pregnancy-and-brain reports to date.

FDA Clears Atacicept (Trutakna) as the First Dual-Target Drug for IgA Nephropathy

On 7 July 2026, the U.S. Food and Drug Administration granted accelerated approval to atacicept-vymj (Trutakna), developed by Vera Therapeutics, for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression. The approval marks a pharmacological first: Trutakna is the only approved therapy that simultaneously blocks both BAFF (B-cell activating factor) and APRIL — two cytokines that sit at the top of the disease's immune cascade, driving the kidney damage characteristic of IgAN.

IgA nephropathy is an autoimmune kidney disease in which abnormally glycosylated immunoglobulin A deposits in the glomeruli — the kidney's filtering units — triggering immune complex formation, inflammation, and progressive scarring. It is a leading cause of kidney failure in adults worldwide and often progresses silently over years before a diagnosis is made. The pivotal ORIGIN 3 trial found that atacicept-treated patients achieved a 46% reduction in proteinuria from baseline, with a statistically significant 42% greater reduction than placebo at 36 weeks. Trutakna is self-administered via a weekly subcutaneous autoinjector at home.

The approval is accelerated, meaning it rests on a surrogate endpoint — proteinuria reduction — rather than direct, long-term evidence of preserved kidney function. The confirmatory portion of ORIGIN 3, a blinded and placebo-controlled extension, is due to report kidney-function data in Q3 2026. A favourable readout there would be expected to support conversion to full approval.

Legionnaires' Cluster Grows on New York's Upper East Side — 46 Cases, 31 Buildings Implicated

New York City health authorities are managing a growing Legionnaires' disease outbreak on the Upper East Side, with 46 confirmed cases recorded between 2 and 9 July 2026. At least 21 patients have been hospitalised; no deaths have been reported. The outbreak is concentrated in the Carnegie Hill, Yorkville, and Lenox Hill neighbourhoods (ZIP codes 10028, 10128, and 10075). City health investigators have detected Legionella bacteria in the cooling towers of 31 buildings, including residential blocks, medical offices, a Whole Foods market, and the Guggenheim Museum.

Legionella pneumophila multiplies in warm standing water inside cooling tower systems and spreads when contaminated droplets are aerosolised and inhaled. It does not spread from person to person, nor through drinking water. Legionnaires' disease causes severe pneumonia; people at highest risk include those over 50, smokers, and individuals with chronic lung disease, diabetes, or immunosuppression. According to CIDRAP, this outbreak is one of several concurrent US public-health events this week.

Compliance concerns shadow the response. A strengthened New York City law requiring cooling tower operators to test regularly for Legionella entered force on 8 May 2026, but uptake among building operators has been limited. Summer is peak Legionnaires' season across the Northern Hemisphere — and in Mediterranean urban centres, hotels, and tourist facilities where rooftop cooling towers are common, the same seasonal risk applies. Travellers with underlying lung conditions or immunosuppression should remain aware, particularly in indoor settings with large air-handling systems.

E. Coli Outbreak Linked to Frozen Organic Blueberries — Recall Issued in Two US States

The U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are investigating an E. coli O145:H28 outbreak linked to GreenWise brand organic frozen blueberries sold at Publix supermarkets in Florida and Georgia. As of early July 2026, 12 illnesses have been confirmed and four people hospitalised. A product recall is in place; consumers who purchased GreenWise-brand frozen organic blueberries are advised to discard or return the product without eating it.

E. coli O145 can cause bloody diarrhoea and haemorrhagic colitis, and in a minority of cases — particularly in young children and older adults — haemolytic uraemic syndrome (HUS), a life-threatening complication that damages the kidneys and blood-forming system. The outbreak strain is not E. coli O157:H7, the type most commonly reported in North American outbreaks, which underscores the importance of clinical testing rather than assumption when diarrhoeal illness is severe or prolonged.

Frozen berries have been a recurrent vehicle for both E. coli and hepatitis A in European and North American outbreaks over the past decade, and the European Food Safety Authority (EFSA) has flagged frozen soft fruit as a high-risk category in previous safety assessments. A point worth emphasising for readers across the Mediterranean: standard home freezing does not kill E. coli. Thorough cooking — bringing berries to 70°C or above — remains the only reliable decontamination method before consumption.

The content above is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health management.